Precision BioSciences to Report First Quarter 2023 Results on May 9, 2023
02 Maio 2023 - 8:00AM
Business Wire
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage
gene editing company developing ARCUS®-based ex vivo allogeneic CAR
T and in vivo gene editing therapies, today announced that it will
publish financial results for the first quarter 2023 and provide a
business update on May 9, 2023.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology
company dedicated to improving life (DTIL) with its novel and
proprietary ARCUS® genome editing platform. ARCUS is a highly
specific and versatile genome editing platform that was designed
with therapeutic safety, delivery, and control in mind. Using
ARCUS, the Company’s pipeline consists of multiple “off-the-shelf”
CAR T immunotherapy clinical candidates and several in vivo gene
editing therapy candidates designed to cure genetic and infectious
diseases where no adequate treatments exist. For more information
about Precision BioSciences please visit
www.precisionbiosciences.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230502005091/en/
Investor and Media Contact: Mei Burris Director, Investor
Relations and Finance Mei.Burris@precisionbiosciences.com
Precision BioSciences (NASDAQ:DTIL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Precision BioSciences (NASDAQ:DTIL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024